Statement by the Board of Directors of Aerocrine in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Statement by the Board of Directors of Aerocrine in relation to Circassia’s public cash offer

The Board of Directors of Aerocrine unanimously recommends Aerocrine’s shareholders to accept the offer by Circassia. NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Background This statement is made by the Board of Directors of Aerocrine AB (the “Board”) pursuant to Section II.19 of Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). Circassia Pharmaceuticals plc has today announced a public cash offer to Aerocrine’s shareholders to sell their Aerocrine shares to Circassia (the “Offer”). Circassia is offering SEK 2.55 per Aerocrine share (the “Offer Price”). The total value of the Offer, based on 698,766,052 shares in Aerocrine, amounts to SEK 1,781,853,433.[1] (http://file///H:/EDRI/Press%20releases/1.%20Board%20recommend a tion/ENG/Board%20recommendation.DOCX#_ftn1) The Offer Price corresponds to a premium of: 85 per cent to Aerocrine’s undisturbed closing price on April 22, 2015, and premiums of 92 per cent and 99 per cent to the three month and six month volume -weighted average prices preceding April 22, 2015. The Offer represents a multiple of 8.7x EV/LTM sales.[2] (http://file///H:/EDRI/Press%20releases/1.%20Board%20recommendation/EN G /Board%20recommendation.DOCX#_ftn2) The acceptance period of the Offer is expected to commence on May 19, 2015 and expire on June 11, 2015, subject to any extensions. The completion of the Offer is conditional upon, amongst other things, being accepted to such an extent that Circassia becomes the owner of more than 90 per cent of the total number of shares in Aerocrine, approval of the transaction and the equity financing by Circassia’s shareholders and the receipt of all necessary regulatory, governmental or similar clearances, approvals and decisions, including from competition authorities, in each case on terms which, in Circassia’s opinion, are acceptable. Circassia has reserved the right to waive these and other conditions for completion of the Offer. The Board has, at the written request of Circassia, permitted Circassia to carry out a confirmatory due diligence review of Aerocrine in connection with the preparation of the Offer. In connection with such due diligence review Circassia has received information concerning Aerocrine’s financial results with respect to the first quarter 2015. Aerocrine’s report for the first quarter 2015 was announced on May 12, 2015. Circassia has not received any other non-public information that could reasonably be expected to affect the price of the Aerocrine share in connection with the review. Novo A/S and Investor AB, Aerocrine’s largest shareholders, with shareholdings representing approximately 50% of the total number of shares and votes in Aerocrine, have under separate agreements with Circassia undertaken to accept the Offer subject to certain conditions (please refer to Circassia’s announcement of the Offer for more information about this acceptance undertaking). As a result of Novo A/S and Investor AB having undertaken to accept the Offer subject to certain conditions, Michael Shalmi and Lennart Johansson have not participated in the Board’s decision regarding the statement of the Board in relation to the Offer. The Board has retained Moelis & Company UK LLP as financial adviser and Mannheimer Swartling Advokatbyrå as legal adviser in relation to the Offer. Nordea Bank AB has at the request of the Board provided an opinion according to which the Offer Price is fair to Aerocrine’s shareholders from a financial point of view (subject to the assumptions and considerations set out in the opinion) (the “Opinion”). The Opinion is attached to this statement. The Board’s evaluation of the Offer The Board has taken into account a number of factors that the Board has considered relevant to the assessment of the Offer. These include, but are not limited to, Aerocrine’s current business and financials and Aerocrine’s potential future development as well as related opportunities and risks. In particular, the Board has taken into account Aerocrine’s ability, on a stand -alone basis, to continue driving commercialisation and adoption of FeNO and development and penetration of markets in Asia, Europe and US; ability to drive penetration in defined US professional segments; ability to attain profitability and any potential future financing requirements; and ability to finalise and commercialise a home device product. It is the opinion of the Board that the combined company will be well positioned as a fully integrated speciality pharma company, with a platform to become the allergy/asthma speciality pharma champion. Moreover, it is the Board’s opinion that the Offer Price reflects the fair value of Aerocrine and represents an attractive premium to Aerocrine’s shareholders. In arriving at its recommendation, the Board has also considered the Opinion rendered by Nordea Bank AB according to which the Offer Price is fair to Aerocrine’s shareholders from a financial point of view (subject to the assumptions and considerations set out in the Opinion). The Board notes that Aerocrine’s credit agreement with ROS Acquisition Offshore LP (an affiliate of OrbiMed Advisors LLC) and Novo A/S, dated April 29, 2013 contains change of control provisions, giving the lenders a right to declare outstanding credit amounts due and payable along with prepayments penalties associated with such acceleration. The effect of any such acceleration would be that Aerocrine would be required to pay a prepayments penalty equal to 50 per cent of the amount being prepaid. However, if the entire amount of the loan is prepaid, the penalty would be reduced by interest and milestone payments already paid. The change of control provisions would be triggered if a party would acquire shares representing more than 40 per cent of the votes of Aerocrine. This means that in case Circassia completes the Offer, even if such completion is made at a lower acceptance level than more than 90 per cent of the shares, the payment under the credit agreement may be accelerated and the prepayment penalty may become due and payable. This may adversely affect Aerocrine’s financial position, leading to an earlier requirement for further capital contribution from shareholders and/or lenders, which the Board would like to highlight to the shareholders who decide not to tender their shares. Under the Takeover Rules the Board is required, on the basis of Circassia’s statements in the announcement of the Offer, to make public its opinion of the effects the implementation of the Offer may have on Aerocrine, specifically employment, and its views on Circassia’s strategic plans for Aerocrine and the effect these may be expected to have on employment and the places where Aerocrine carries on its business. Circassia has in this respect stated that Circassia appreciates the work of Aerocrine’s management team and dedicated employees. Circassia’s future plan for Aerocrine is one of growth. In view of the complementary nature of Circassia’s and Aerocrine’s businesses, the envisaged integration between the companies is expected to generally have a limited effect on the employee relationships at Aerocrine as well as on the future businesses of both companies. Even though changes may occur with respect to certain functions or positions at both companies, the current view of Circassia is that there will not be any material change to Aerocrine’s operational sites or its employees, including the employee’s terms of employment. The Board assumes that this description is accurate and has in relevant aspects no reason to take a different view. Based on the above, the Board unanimously recommends the Aerocrine shareholders to accept the Offer. ___________ This statement shall in all respects be governed by and construed in accordance with substantive Swedish law. Disputes arising from this statement shall be settled exclusively by Swedish courts. This statement has been made in a Swedish and English version. In case of any discrepancies between the Swedish and the English text, the Swedish text shall prevail. ___________ Stockholm, May 15, 2015 Aerocrine The Board of Directors The information set out in this press release is announced in accordance with the Swedish Securities Markets Act and the Takeover Rules. The Information was submitted for publication on May 15, 2015 at 08:30 CET. This press release may not be published, distributed, transmitted or otherwise sent into the United States of America (including its territories and possessions, every State in the United States and the District of Columbia), Australia, Canada, Japan or South Africa or any other state or jurisdiction in which such release, publication or distribution would be unlawful.  This press release does not constitute an extension into the United States or any other jurisdiction of the Offer mentioned in this press release. ---------------------------------------------------------------------- [1] (http://file///H:/EDRI/Press%20releases/1.%20Board%20recommendation/ENG/Boar d %20recommendation.DOCX#_ftnref1) On 13 May 2015 (the last trading day prior to the announcement of the Offer), there were 698,766,052 shares in Aerocrine registered with the Swedish Companies Registration Office. Additional shares in Aerocrine may be issued following this point in time as a result of exercise of outstanding personnel stock options and warrants in Aerocrine, and any such additional shares shall be included in the Offer. Aerocine does not hold any own shares in treasury. [2] (http://file///H:/EDRI/Press%20releases/1.%20Board%20recommendation/ENG/Boar d %20recommendation.DOCX#_ftnref2) Enterprise Value includes effect of dilutive instruments at the corresponding offer price, as well as debt and cash items as of March 31, 2015. Sales figure represents last 12 months as of March 31, 2015.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Voltalia Partners with Retail Giants for EV Charging Stations

Updated Category News Views 165

Innovative Partnership to Enhance Electric Vehicle Charging Voltalia, a prominent name in the renewable energy sector, is making significant strides by collaborating with Auchan, DECATHLON, and Leroy Merlin. This partnership aims to deploy electric vehicle (EV) charging stations across more than 350 parking lots in France, marking a crucial step towards fostering...

Continue Reading
Khanh Phuong Morrow's Strategic Insider Move at Lantheus Holdings

Updated Category News Views 211

Khanh Phuong Morrow's Strategic Insider Decision at Lantheus Holdings In a recent filing, it was disclosed that Khanh Phuong Morrow, a Board Member at Lantheus Holdings (NASDAQ: LNTH), exercised stock options leading to a transaction valued at $0. This decision sheds light on the ongoing activities within the company and showcases the actions of key insiders....

Continue Reading
Investors Urged to Stay Informed on Organon & Co. Class Action

Updated Category News Views 170

Class Action Lawsuit Against Organon & Co. Pomerantz LLP has announced the initiation of a class action lawsuit against Organon & Co. This lawsuit primarily targets investors who have suffered losses relating to their investment in Organon (NYSE: OGN). With the launch of this lawsuit, it is essential for affected investors to understand their rights and options available...

Continue Reading
Sionna Therapeutics Faces Legal Scrutiny Amid Stock Plunge

Updated Category News Views 90

Stock Drop Sparks Legal Action August 10, 2026, wasn't exactly a banner day for Sionna Therapeutics' investors. We're talking about watching a stock nosedive by a jaw-dropping 92%, which is the kind of number that'd knock your socks off under normal circumstances. The catalyst? Some dismal results from the company's Phase 2a proof-of-concept study of SION-719 aimed at...

Continue Reading
Toll Brothers Unveils Stunning New Homes in Chapel Oaks

Updated Category News Views 221

Exciting New Model Homes at Chapel Oaks Community CHAPEL HILL, N.C. – Toll Brothers, Inc. (NYSE: TOL), a prominent name in luxury home construction, has recently announced the opening of their latest model home at the Chapel Oaks community. This new community marks a significant addition to their portfolio in the Raleigh area, providing prospective homeowners with...

Continue Reading